Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

46.81 -0.70 (-1.47%)
Delayed Quote Updated: 1:15 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
ANAB stock shows explosive revenue growth and strong technical setup, making it a top momentum pick for biotech investors. 
Via Chartmill
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗
Via Stocktwits
Why Is Eli Lilly’s Stock Slipping Premarket? ↗
Via Stocktwits
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga
News headline image
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗
The company was working on a treatment for ulcerative colitis, using a relatively different approach. 
Via Investor's Business Daily
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗
Markets closed in the green on Tuesday, undeterred by the looming U.S. government shutdown. Pfizer surged nearly 7% on a political deal, while CoreWeave soared after signing a multibillion-dollar AI... 
Via Chartmill
Topics Artificial Intelligence
News headline image
Here are the top movers in Tuesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million. 
Via Benzinga
News headline image
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio (ANAB) Q2 Revenue Jumps 103% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
News headline image
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May ↗
 
Via Benzinga
News headline image
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering ↗
The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.